内容发布更新时间 : 2024/12/23 0:13:10星期一 下面是文章的全部内容请认真阅读。

[214] Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil

and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer(a European Association for Research in Oncology trial). Ann Oncol, 2003, 14: 1537-1542. [215] Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy

for nonresectable colorectal. Ann Surg Oncol, 2001, 8: 347-53.

[216] Adam R, Miller R, Pitombo M, et al. Two-stage hepatectomy appeoach for initially unresectable colorectal

hepatic metastases. Surg Oncol Clin N Am, 2007, 16: 525-536.

[217] Homayounfar K, Liersch T, Schuetze G, et al. Two-stage hepatectomy (R0) with portal vein

ligation--towards curing patients with extended bilobular colorectal liver metastases. Int J Colorectal Dis, 2009, 24: 409-418.

[218] Covey AM, Brown KT, Jamagin WR, et al. Combined portal vein embolization and neoadjuvant

chemotherapy as a treament strategy for resectable hepatic colorectal metastases. Ann Surg, 2008, 247: 451-455.

[219] Yamashita S, Hasegawa K, Takahashi M, et al. One-stage hepatectomy following portal vein embolization

for colorectal liver metastasis. World J Surg, 2013, 37: 622-628.

[220] Wicherts DA, de Haas RJ, Andreani P, et al. Impact of portal vein embolization on long-term survival of

patients with primarily unresectable colorectal liver metastases. Br J Surg, 2010, 97: 240-250.

[221] Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in

patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol, 2012, 23: 948-954.

[222] Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with

unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol, 2005, 23: 9243-9249.

[223] Quenet F, Nordlinger B, Rivoire M. Resection of previously unresctable liver metastases from colorectal

cancer after chemotherapy wiht CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol, 2004, 23: Abstract 3613.

[224] Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer

liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 1999, 10: 663-669.

[225] Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil,

leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer, 2010, 103: 1542-1547.

[226] Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil,

and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol, 2010, 11: 845-852.

[227] Bruera G, Santomaggio A, Cannita K, et al. \association of weekly alternating 5-fluorouracil,

irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer, 2010, 10: 567.

[228] Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus

bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol, 2011, 22: 2042-2048.

[229] Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional

fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010, 28: 4697-4705.

[230] Cassidy J, Cunningham D, Berry SR, et al. Surgery with curative intent in patients(pts) treated wiht first-line

chemotherapy(CT) + bevacizumab(BEV) for metastatic colorectal cancer(mCRC): first BEAT and NO16966. J Clin Oncol, 2008, 26(Suppl 15): Abstract 4022.

[231] Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI(folinic acid, 5-fluorouracil oxaliplatin and

irinotecan) vs FOLFIRI(folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer(MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer, 2006, 94: 798-805.

[232] Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil,

leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer, 2010, 103: 1542-1547.

[233] Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with

availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol, 2005, 23: 9441-9442.

[234] Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment

of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol, 2010, 28: 3191-3198.

[235] Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of

advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol, 2011, 12: 1032-1044.

[236] Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine,

irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 2007, 370: 135-142.

[237] Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination

chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 2007, 370: 143-152.

[238] Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line

treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer, 2012, 11: 38-44.

[239] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for

metastatic colorectal cancer. N Engl J Med, 2004, 350: 2335-2342.

[240] Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic

chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009: CD007823.

[241] Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus

systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2009, 27: 3465-3471.

[242] Gruenberger B, Tamandl D, Puhalla H, et al. Bevacizumab plus XELOX as neoadjuvant chemotherapy for

patients with potentially curable metastatic colorectal cancer. J Clin Oncol, 2007, 25(18 suppl): 179s. [243] Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with

prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 2008 , 26: 5326-5334.

[244] Welch S, Spithoff K, Rumble RB, et al. Bevacizumab combined with chemotherapy for patients with

advanced colorectal cancer: a systematic review. Ann Oncol, 2010, 21: 1152-1162.

[245] Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-?uorouracil/folinic

acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer, 2009, 9: 112.

[246] Van Cutsem E, K?hne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line

treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011, 29: 2011-2019.

[247] Díaz Rubio E, Tabernero J, van Cutsem E. et al. Cetuximab in combination with oxaliplatin/5-fluorouracil

(5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, 2005, 23(16 suppl): 254s.

[248] Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or

oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 2007, 25: 4779-4786.

[249] Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in

patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol, 2012, 30: 3570-3577.

[250] De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in

patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 2010, 304: 1812-1820.

[251] Peeters M, Douillard JY, Van Cutsem E, et al. Evaluation of individual codon 12 and 13 mutant (mt) KRAS

alleles as prognostic and predictive biomarkers of response to panitumumab (pmab) in patients with metastatic colorectal cancer (mCRC). Eur J Cancer, 2011, 47(suppl 2): abstr LBA33.

[252] Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon

cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 2010, 28: 466-474.

[253] Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes

From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol, 2011, 29: 2675-2682.

[254] Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin

D1 expression predict metastatic colorectal patients\ [255] Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional

fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010, 28: 4697-4705.

[256] Tveit K, Guren T. Randomized phase III study of 5-Fluorouracil/folinate/oxaliplatin given continously or

intermittently with or without cetuximab, as firstline treatment of metastatic colorectal cancer: The NORDIC VII study(NCT00145314). Ann Oncol, 2010, 21: LBA 20.

[257] Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to

fluorouracil ? leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol, 2005, 23: 3706-3712.

[258] Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and

leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 2005, 23: 3502-3508. [259] Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of

metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol, 2009, 27: 199-205.

[260] Hoff PM, Eng C, Adinin RB, et al. Preliminary results from a phase II study of FOLFIRI plus bevacizumab

as ?rst-linetreatment for metastatic colorectal cancer (mCRC). ASCO annual meeting proceedings, 2006, 24(Suppl): 165S.

[261] Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX,

XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 2009, 20: 1842-1847.

[262] López R, Salgado M, Reboredo M, et al. A retrospective observational study on the safety and efficacy of

first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer, 2010, 103: 1536-1541.

[263] Chaudhury P, Hassanain M, Bouganim N, et al. Perioperative chemotherapy with bevacizumab and liver

resection for colorectal cancer liver metastasis. HPB (Oxford), 2010, 12: 37-42.

[264] Cartwright TH, Yim YM, Yu E, et al. Survival outcomes of bevacizumab beyond progression in metastatic

colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer, 2012, 11: 238-246. [265] Arnold D, Andre T, Bennouna J, et al. Bevacizumab(BEV) plus chemotheraoy(CT) continued beyond first

progression in patients with metastatic colorectal cancer(mCRC) previously treated with BEV plusCT: Results of a randomized phase III intergroup study(TML study). J Clin Oncol, 2012, 30(15 suppl): CRA3503.

[266] Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from

nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1, 290 patients. Cancer, 2010, 116: 5608-5618.

[267] Starlinger P, Alidzanovic L, Schauer D, et al. Neoadjuvant bevacizumab persistently inactivates VEGF at the

time of surgery despite preoperative cessation. Br J Cancer, 2012, 107: 961-966.

[268] Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal

cancer. N Engl J Med, 2009, 360: 563-572.

[269] Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and

panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol, 2009, 27: 672-680.

[270] Spigel DR, Greco FA, Waterhouse D, et al. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the

first-line treatment of metastatic colorectal cancer. Clin Adv Hematol Oncol, 2010, 8: 480-5, 498.

[271] Hammill CW, Billingsley KG, Cassera MA, et al. Outcome after laparoscopic radiofrequency ablation of

technically resectable colorectal liver metastases. Ann Surg Oncol, 2011, 18: 1947-1954.

[272] Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency

ablation: complications encountered in a multicenter study. Radiology, 2003, 226: 441-451.

[273] Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma. Cancer

Control, 2006, 13: 48-51.

[274] Vauthey JN, Zorzi D, Pawlik TM. Making unresectable hepatic colorectal metastases resectable—does it

work? Semin Oncol, 2005, 32(Suppl 9): S118-S122.

[275] Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection,

radiofrequency ablation, and combined resection/ablation for colorectal liver metastasis. Ann Surg. 2004;239: 818-825.

[276] Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review.

Colorectal Dis, 2011, 13: e252-e265.

[277] Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of

colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol, 2011, 22: 755-761. [278] Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver

metastases : 10-year experience. Ann Surg, 2007, 246: 559-567.

[279] Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radio frequency thermal ablation of

solitary colorectal liver metastasis. J Gastrointest Surg, 2008, 12: 1967-1972.

[280] Knudsen AR, Kannerup AS, Mortensen FV, et al. Radiofrequency ablation of colorectal liver metastases

downstaged by chemotherapy. Acta Radiol, 2009, 50: 716-721.

[281] Brouquet A, Andreou A, Vauthey JN. The management of solitary colorectal liver metastases. Surgeon,

2011, 9: 265-272.

[282] Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons

learned. Oncologist, 2001, 6: 24-33.

[283] Van Tilborg AA, Meijerink MR, Sietses C, et al. Long-term results of radiofrequency ablation for

unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol, 2011, 84: 556-565. [284] Curley SA, Izzo F. Radiofrequency ablation of hepatocellular carcinoma. Minerva Chir, 2002, 57: 165-176. [285] Lu DS, Raman SS, Limanond P, et al. In?uence of large peritumoral vessels on outcome of radiofrequency

ablation of liver tumors. J Vasc Interv Radiol, 2003, 14: 1267-1274.

[286] Elias D, Di Pietroantonio D, Gachot B, et al. Liver abscess after radiofrequency ablation of tumors in

patients with a biliary tract procedure. Gastroenterol Clin Biol, 2006, 30: 823-827.

[287] Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology, 2007, 72 Suppl 1: 124-131. [288] Zhang X, Zhou L, Chen B, et al. Microwave ablation with cooled-tip electrode for liver cancer: an analysis

of 160 cases. Minim Invasive Ther Allied Technol, 2008, 17: 303-307.

[289] Shono Y, Tabuse K, Tsuji T, et al. Microwave coagulation therapy for unresectable colorectal metastatic

liver tumor. Gan To Kagaku Ryoho, 2002, 29: 856-859.

[290] Grundmann RT, Hermanek P, Merkel S, et al. Diagnosis and treatment of colorectal liver metastases -

workflow. Zentralbl Chir, 2008, 133: 267-284.

[291] Seifert JK, Junginger T. Prognostic factors for cryotherapy of colorectal liver metastases. Eur J Surg Oncol,

2004, 30: 34-40.

[292] Chen YY, Perera DS, Yan TD, et al. Applying Fong\CRS liver score in patients with colorectal liver

metastases treated by cryotherapy. Asian J Surg, 2006, 29: 238-241.

[293] Seifert JK, Junginger T. Cryotherapy for liver tumors: current status, perspectives, clinical results, and

review of literature. Technol Cancer Res Treat, 2004, 3: 151-163.

[294] Gignoux BM, Ducerf C, Mabrut JY, et al. Cryosurgery of primary and metastatic cancers of the liver. Ann

Chir, 2001, 126: 950-959.

[295] Austin-Seymour MM, Chen GT, Castro JR, et al. Dose volume histogram analysis of liver radiation

tolerance. Int J Radiat Oncol Biol Phys, 1986, 12: 31-35.

[296] Eble MJ, Gademann G, Wannenmacher M, et al. The value of radiotherapy for liver metastases. Strahlenther

Onkol, 1993, 169: 459-468.

[297] Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body

radiation therapy for liver metastases. J Clin Oncol, 2009, 27: 1572-1578.

[298] Ingold JA, Reed GB, Kaplan HS, et al. Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med, 1965,

93: 200-208.

[299] Yeo SG, Kim DY, Kim TH, et al. Whole-liver radiotherapy for end-stage colorectal cancer patients with

massive liver metastases and advanced hepatic dysfunction. Radiat Oncol, 2010, 5: 97.

[300] Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic

metastases from colorectal cancer. J Clin Oncol, 1996, 14: 722-728.

[301] Robertson JM, McGinn CJ, Walker S, et al. A phase l trial of hepatic arterial bromodeoxyuridine and

conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. J Rad Oncol Biol Phys, 1997, 39: 1087-1092.

[302] Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver

metastases. J Clin Oncol, 2009, 27: 1585-1591.

[303] Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body

radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys, 2010, 78: 486-493.

[304] Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy:

long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys, 2012, 83: 878-886.

[305] Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a

pooled analysis. Cancer, 2011, 117: 4060-4069.

[306] Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys, 2005, 62: 1371-1378.

[307] Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys, 2007, 67: 793-798.